hiPS derived cardiomyocytes
transcriptome level
hiPSC derived cardiomyocytes
development of HF
specific forms of HF
anthracycline-induced HF
molecular level cardiac tissue
new onset HF
endothelial cells
D cardiac tissue
high susceptibility
RESILIENCE
Generation of patient specific cardiac cells
Integration of transcriptome data
specific forms of heart failure
early development of
SPECIFIC OBJECTIVES
human induced pluripotent stem cells
hiPSC technology
patients
inter-individual susceptibility
clear trigger
Better understanding of early molecular pathways
maturation
pregnancy
Validation of novel pathways
overlapping pathways
Fabrication
general population
detection of early changes
overarching objective of STOP
non-coding RNAs
STEM CELL MODELS
PPCM
skin fibroblasts
knowledge
healthy sisters
common pathophysiological mechanisms
females
results
project
differences
anthracyclins
WP3
WP4
anthracyclines
innovative approach
WP1
discoveries
WP2A
WP2B
WORKPACKAGES